104 related articles for article (PubMed ID: 27386594)
21. Clinical utility of milnacipran in comparison with other antidepressants.
Bisserbe JC
Int Clin Psychopharmacol; 2002 Jun; 17 Suppl 1():S43-50. PubMed ID: 12369610
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect?
Perahia DG; Pritchett YL; Desaiah D; Raskin J
Int Clin Psychopharmacol; 2006 Nov; 21(6):311-7. PubMed ID: 17012978
[TBL] [Abstract][Full Text] [Related]
23. Milnacipran for treatment of fibromyalgia.
Kyle JA; Dugan BD; Testerman KK
Ann Pharmacother; 2010 Sep; 44(9):1422-9. PubMed ID: 20716692
[TBL] [Abstract][Full Text] [Related]
24. Effect of spinal monoaminergic neuronal system dysfunction on pain threshold in rats, and the analgesic effect of serotonin and norepinephrine reuptake inhibitors.
Tamano R; Ishida M; Asaki T; Hasegawa M; Shinohara S
Neurosci Lett; 2016 Feb; 615():78-82. PubMed ID: 26806036
[TBL] [Abstract][Full Text] [Related]
25. Clinical experience with dual action antidepressants in different chronic pain syndromes.
Briley M
Hum Psychopharmacol; 2004 Oct; 19 Suppl 1():S21-5. PubMed ID: 15378667
[TBL] [Abstract][Full Text] [Related]
26. Management of depression in the presence of pain symptoms.
Mohr P; Bitter I; Svestka J; Seifritz E; Karamustafalioglu O; Koponen H; Sartorius N
Psychiatr Danub; 2010 Mar; 22(1):4-13. PubMed ID: 20305585
[TBL] [Abstract][Full Text] [Related]
27. New hope in the treatment of painful symptoms in depression.
Briley M
Curr Opin Investig Drugs; 2003 Jan; 4(1):42-5. PubMed ID: 12625027
[TBL] [Abstract][Full Text] [Related]
28. Permanent relief from intermittent cold stress-induced fibromyalgia-like abnormal pain by repeated intrathecal administration of antidepressants.
Nishiyori M; Uchida H; Nagai J; Araki K; Mukae T; Kishioka S; Ueda H
Mol Pain; 2011 Sep; 7():69. PubMed ID: 21933442
[TBL] [Abstract][Full Text] [Related]
29. Tricyclic antidepressants and fibromyalgia: what is the mechanism of action?
Lawson K
Expert Opin Investig Drugs; 2002 Oct; 11(10):1437-45. PubMed ID: 12387704
[TBL] [Abstract][Full Text] [Related]
30. Effect of milnacipran on extracellular monoamine concentrations in the medial prefrontal cortex of rats pre-treated with lithium.
Kitaichi Y; Inoue T; Nakagawa S; Izumi T; Koyama T
Eur J Pharmacol; 2005 Jun; 516(3):219-26. PubMed ID: 15963494
[TBL] [Abstract][Full Text] [Related]
31. Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: comparison between milnacipran and paroxetine.
Ikenouchi-Sugita A; Yoshimura R; Hori H; Umene-Nakano W; Ueda N; Nakamura J
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1451-3. PubMed ID: 19664676
[TBL] [Abstract][Full Text] [Related]
32. A probable case of movement disorder (Tardive dyskinesia) due to duloxetine treatment.
Yılmaz R; Üstün D; Tuncer Uzun S; Reisli R; Türk Ş
Agri; 2018 Oct; 30(4):199-201. PubMed ID: 30403275
[TBL] [Abstract][Full Text] [Related]
33. Combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized-controlled trial.
Ang DC; Jensen MP; Steiner JL; Hilligoss J; Gracely RH; Saha C
Clin J Pain; 2013 Sep; 29(9):747-54. PubMed ID: 23446065
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic profiles contribute to the differences in behavioral pharmacology of 071031B enantiomers as novel serotonin and norepinephrine reuptake inhibitors.
Xue R; Li Y; He XH; Jin ZL; Fan SY; Zhang TT; Li NM; Yuan L; Zheng AP; Zhong BH; Li YF; Zhang YZ
J Psychopharmacol; 2017 Mar; 31(3):377-386. PubMed ID: 28245750
[TBL] [Abstract][Full Text] [Related]
35. Effects of milnacipran on the multidimensional aspects of fatigue and the relationship of fatigue to pain and function: pooled analysis of 3 fibromyalgia trials.
Mease PJ; Palmer RH; Wang Y
J Clin Rheumatol; 2014 Jun; 20(4):195-202. PubMed ID: 24847745
[TBL] [Abstract][Full Text] [Related]
36. Milnacipran in the treatment of bulimia nervosa: a report of 16 cases.
El-Giamal N; de Zwaan M; Bailer U; Strnad A; Schüssler P; Kasper S
Eur Neuropsychopharmacol; 2003 Mar; 13(2):73-9. PubMed ID: 12650949
[TBL] [Abstract][Full Text] [Related]
37. A comparative study of milnacipran and imipramine in the treatment of major depressive disorder.
Lopez-Ibor JJ; Conesa A;
Curr Med Res Opin; 2004 Jun; 20(6):855-60. PubMed ID: 15200743
[TBL] [Abstract][Full Text] [Related]
38. Functional magnetic resonance imagery (fMRI) in fibromyalgia and the response to milnacipran.
Mainguy Y
Hum Psychopharmacol; 2009 Jun; 24 Suppl 1():S19-23. PubMed ID: 19479905
[TBL] [Abstract][Full Text] [Related]
39. Contributions of change in clinical status parameters to Patient Global Impression of Change (PGIC) scores among persons with fibromyalgia treated with milnacipran.
Geisser ME; Clauw DJ; Strand V; Gendreau MR; Palmer R; Williams DA
Pain; 2010 May; 149(2):373-378. PubMed ID: 20332060
[TBL] [Abstract][Full Text] [Related]
40. Effect of Milnacipran on Plasma Level of Vascular Endothelial Growth Factor in Major Depression.
Yoshimura R; Ikenouchi A; Okamoto N
Psychopharmacol Bull; 2022 Oct; 52(4):106-108. PubMed ID: 36339278
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
